An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas

Annals of Oncology

Volumn 24, Issue 1, 2013, Pages 257-263

  Agulnik, M ^a   Yarber, J L ^a   Okuno, S H ^b   von Mehren, M ^c   Jovanovic, B D ^d   Brockstein, B E ^a   Evens, A M ^a   Benjamin, R S ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiosarcoma; Bevacizumab; Hemangioendotheliomas; Soft tissue sarcoma

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANGIOSARCOMA; ANOREXIA; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; CANCER GROWTH; CANCER PROGNOSIS; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CYTOKINE RELEASE SYNDROME; DEMENTIA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; ENZYME DEFECT; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; HEMANGIOENDOTHELIOMA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; INFUSION RELATED REACTION; LIVER DISEASE; MALE; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; OPEN STUDY; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEINURIA; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT RESPONSE; VEIN THROMBOSIS; WOUND DEHISCENCE;

EID: 84876506864     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds237     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Wanebo HJ, Koness RJ, MacFarlane JK et al. Head and neck sarcoma: report of the Head and Neck Sarcoma Registry. Society of Head and Neck Surgeons Committee on Research. Head Neck 1992; 14: 1.
3. Weber RS, Benjamin RS, Peters LJ et al. Soft tissue sarcomas of the head and neck in adolescents and adults. Am J Surg 1986; 152: 386.
4. Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphadema. Cancer 1948; 1: 17.
5. Stewart FW, Treves N. Classic in oncology: lymphangiosarcoma in postmastectomy lymphedema: a report of six cases in elephantiasis chirurgica. CA Cancer J Clin 1981; 31: 15.
6. Heath CW, Jr, Falk H, Creech JL, Jr. Characteristics of cases of angiosarcoma of the liver among vinyl chloride workers in the United States. Ann N Y Acad Sci 1975; 246: 231-236.
7. Fodor J, Orosz Z, Szabo E et al. Angiosarcoma after conservation treatment for breast carcinoma: our experience and a review of the literature. J Am Acad Dermatol 2006; 54: 499-504.
8. Zelek L, Llombart-Cussac A, Terrier P et al. Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol 2003; 21: 2583-2588.
9. Antman K, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and decarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11: 9.
10. Baker LH, Frank J, Fine G et al. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613). J Clin Oncol 1987; 5: 10.
11. Borden EC, Amato DA, Rosenbaum C et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5: 10.
12. Endomson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 6.
13. Verweji J, Lee SM, Ruka W et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 2000; 18: 5.
14. Fata F, O'Reilly E, Ilson D et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999; 86: 3.
15. Schlemmer M, Reichardt P, Verweji J. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2008; 44: 3.
16. JF. Antiangiogenic therapy. In Cancer: Principles and Practice of Oncology, 5th edition. Philadelphia: Lippincott-Raven 1997; 3075-3085.
17. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 21.
18. Itakura E, Yamamoto H, Oda Y et al. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol 2008; 97: 7.
19. Taylor KL, Oates RK, Grane R et al. IFN-alpha 1,8 inhibits tumor-induced angiogenesis in murine angiosarcomas. J Interferon Cytokine Res 2006; 26: 8.
20. Koontz BF, Miles EF, Rubio MA et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck 2008; 30: 4.
21. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumor: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 11.
22. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-smallcell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
23. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 7.
24. Miller K, Wang M, Gralow J. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 10.
25. Young RJ, Brown NJ, Reed MW et al. Angiosarcoma. Lancet Oncol 2010; 11: 8.
26. Pawlik TM, Paulino A, McGinn CJ et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 2003; 98: 10.
27. Lahat G, Dhuka AR, Hallevi H et al. Angiosarcoma: clinical and molecular insights. Ann Surg 2010; 251: 1098.
28. Lydiatt WM, S A, Shah JP. Angiosarcoma of the head and neck. Am J Surg 1994; 168: 451.
29. Penel N, Bui BN, Bay JO et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008; 26: 5269-5274.
30. George S, Merriam P, Maki RG et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009; 27: 6.
31. Maki RG, D'Adamo DR, Keohan MI et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27: 7.
32. Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist 2005; 10: 833-841.
33. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
34. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-3247.
35. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-1260.
36. Kelly WK, Halabi S, Carducci M, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J Clin Oncol 2010; ASCO Meeting Abstracts.
37. Burger RA, Brady MA, Bookman JL et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol 2010; ASCO Meeting Abstracts.
38. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall- cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-1234.
39. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
40. Reck M, von Pawel J, Zatloukal P et al. Overall survival with cisplatingemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21: 1804-1809.
41. Kindler HL, Niedzwiecki D, Hollis D et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28: 3617-3622.
42. Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 2231-2237.
43. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
44. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
45. D'Adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005; 23: 7135-7142.